誉衡药业：与兴和制药签订佩玛贝特片推广协议

Core Viewpoint - The announcement highlights a collaboration between Yuheng Pharmaceutical and Xinghe Pharmaceutical for the promotion of Pemabate Tablets, which is expected to enhance Yuheng's product line and competitiveness in the cardiovascular field [1]. Group 1 - Yuheng Pharmaceutical signed a co-promotion agreement with Xinghe Pharmaceutical on May 23, 2025, for Pemabate Tablets [1]. - The agreement will take effect on June 1, 2025, with an initial term until December 31, 2027, and it can be automatically renewed thereafter [1]. - Xinghe Pharmaceutical authorizes Yuheng Pharmaceutical to promote Pemabate Tablets in designated areas and will pay service and promotional support fees [1]. Group 2 - Pemabate Tablets are the world's first novel high-selectivity PPARα modulator, primarily used to lower triglyceride levels in adult patients with non-familial hypertriglyceridemia [1]. - This collaboration is expected to enrich Yuheng Pharmaceutical's product portfolio and strengthen its competitive position in the cardiovascular sector [1].